- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05358691
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Primary
- Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation)
- Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory
- Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab
Study Overview
Detailed Description
The purpose of the research is to evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in advanced (Stage III) Non-Small Cell Lung Cancer. Participant will receive the experimental combination of drugs (AN0025, chemoradiation and durvalumab) and undergo laboratory tests and study procedures on specified days during the study period. Complete end of study evaluations and tests, and participate in post-study follow up every three months for two years. The time in the study will take approximately four to six hours during pre-study, study and end of study visits.
Possible benefits of taking part may be improvement in your condition and slowing or stopping the growth of your cancer.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Salma K Jabbour, MD
- Phone Number: (732) 253-3939
- Email: jabbousk@cinj.rutgers.edu
Study Contact Backup
- Name: Matthew Deek, MD
- Phone Number: (732) 253-3941
- Email: Deekmp@cinj.Rutgers.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Contact:
- Salma Jabbour
- Phone Number: 732-253-3961
- Email: jabbousk@cinj.rutgers.edu
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Matthew Deek, MD
- Phone Number: (732) 253-3941
- Email: Deekmp@cinj.Rutgers.edu
-
Contact:
- Salma K Jabbour, MD
- Phone Number: 732-253-3939
- Email: jabbousk@cinj.rutgers.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be willing and able to provide written informed consent for the trial
- Age 18 years or greater
- Be fully active, able to carry on all pre-disease performance without restriction or restricted in physically strenuous activity but able to carry out work of a light or sedentary nature (e.g., light house work, office work)
- Be diagnosed with confirmed locally advanced and nonresectable, or metastatic Stage III Non-Small Cell Lung Cancer
- Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Adequate staging of your disease
- Adequate lung function
- Adequate other organ functions
- No active second cancers
- Be willing and able to comply with all aspects of the protocol
- Female patients of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication
- Female participants of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
- Male participants should agree to abstinence or use of an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
Exclusion Criteria:
- Age less than 18 years
- Weight less than 30 Kg (~66 lbs)
- Pregnant or breastfeeding women
- Have been discontinued in a prior treatment study with immunotherapy drugs due to a severe toxicity (Grade 3 or higher)
- Received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
- Had an allogenic tissue/solid organ transplant
- A diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to the first dose of study drug
- Known active cancer spread to central nervous system
- Known severe hypersensitivity to study treatment components
- An active autoimmune disease that has required systemic treatment in the past two years
- Have inflammatory bowel disease
- Have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis
- Have a history of interstitial lung disease
- Have an active infection requiring systemic therapy
- Have human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections,
- Have abnormal electrocardiogram (Prolongation of QT interval)
- Significant cardiovascular impairment: history of congestive heart failure, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia
- Major surgery within four weeks before the first dose of study drug
- Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting)
- Have a known psychiatric or substance abuse problems
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AN0025: Dose level one: 250 mg daily
Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
|
To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
Other Names:
|
Experimental: AN0025: Dose level two: 375 mg daily
Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
|
To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eastern Cooperative Oncology Group Performance Status (ECOGPS) to measure how participants disease is progressing
Time Frame: Two years
|
The performance status will be assessed according to the Eastern Cooperative Oncology Group Performance Status (ECOG) performance status scale.
Eastern Cooperative Oncology Group Performance Status (ECOG) will be measured at screening, at day one of each treatment cycle and at the safety follow-up visits
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune response evaluation criteria in solid tumors( iRECIST) to measure the progression of disease
Time Frame: 2 years
|
A solid tumor measurement and definitions for objective change in tumor size.
Immune response evaluation criteria in solid tumors (iRECIST) is based on RECIST 1.1, but adapted to account for the unique tumor response seen with immunotherapeutic drugs.
iRECIST will be used by the Investigator to assess tumor response and progression and make treatment decisions.
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response evaluation criteria in solid tumors (RECIST 1.1) will be used as the primary measure for tumor response
Time Frame: 2 Years
|
Response evaluation criteria in solid tumors (RECIST 1.1) will be used as the primary measure for evaluation of tumor response and date of disease progression
|
2 Years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Salma K Jabbour, MD, Rutgers Cancer Institute of New Jersey
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 032303
- Pro2022000665 (Other Identifier: Rutgers, The State University of New Jersey)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer Stage III
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIC Lung Cancer AJCC v8 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7United States
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Biomea Fusion Inc.RecruitingColorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditionsUnited States, Korea, Republic of
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage IV Lung Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Malignant Female Reproductive System Neoplasm | Stage III... and other conditionsUnited States
-
Blue Note TherapeuticsTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Not yet recruitingStage IV Lung Cancer | Stage III Lung Cancer | Stage II Lung Cancer
-
Barbara Ann Karmanos Cancer InstituteCompletedStage IV Lung Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage III Breast Cancer | Stage IV Colorectal Cancer | Stage IV Ovarian Cancer | Stage III Lung Cancer | Stage III Cervical Cancer and other conditionsUnited States
-
Mayo ClinicCompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Breast AdenocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage II Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage I Pancreatic Cancer | Stage II Non-small Cell Lung Cancer | Stage III Colon Cancer and other conditionsUnited States
Clinical Trials on AN0025
-
Adlai Nortye Biopharma Co., Ltd.Recruiting
-
Adlai Nortye Biopharma Co., Ltd.Merck Sharp & Dohme LLCActive, not recruitingCervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)United States, France
-
Adlai Nortye Biopharma Co., Ltd.RecruitingLocally Advanced Solid TumorUnited States